Welcome to our dedicated page for Opus Genetics news (Ticker: IRD), a resource for investors and traders seeking the latest updates and insights on Opus Genetics stock.
Opus Genetics, Inc. (Nasdaq: IRD) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), along with small-molecule therapies for other ophthalmic disorders. The IRD news feed for IRD on Stock Titan aggregates company-issued updates, press releases, and regulatory communications that describe the progress of these programs.
Readers following Opus Genetics news can expect coverage of clinical trial milestones for its lead gene therapy candidates, including OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for BEST1-related retinal degeneration and Best disease. The company regularly reports on Phase 1/2 and planned pivotal trial activities, safety and efficacy observations, and feedback from the U.S. Food and Drug Administration, such as outcomes of Regenerative Medicine Advanced Therapy (RMAT) meetings and regulatory designations.
News items also highlight pipeline expansion and preclinical work in programs targeting genes such as RHO, CNGB1, RDH12, NMNAT1, and MERTK, as well as partnerships with patient advocacy groups that provide non-dilutive funding and community engagement in rare retinal diseases. In addition, Opus Genetics issues updates on its small-molecule program, Phentolamine Ophthalmic Solution 0.75%, including supplemental New Drug Application plans and Phase 3 trials in presbyopia and low-light visual disturbances following keratorefractive surgery.
Investors and observers can also find corporate and financing announcements, such as registered direct offerings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and conference participation at healthcare and ophthalmology events. By reviewing the IRD news page, users can track how Opus Genetics describes the evolution of its ophthalmic gene therapy and drug development pipeline over time.
Opus Genetics (Nasdaq: IRD) announced that leadership will present program updates at multiple ophthalmology and gene‑therapy conferences in May 2026, including ARVO (May 3–7), ASGCT (May 11–15), Retina World Congress (May 14–17) and the Retinal Therapeutics Innovation Summit (May 1).
Presentations will cover preliminary Phase 1b/2a OPGx-BEST1 clinical data, preclinical OPGx-RHO work, and translational assays advancing their inherited retinal disease pipeline.
Opus Genetics (NASDAQ: IRD) will present three abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, 2026. Presentations include full Phase 3 VEGA-3 results for phentolamine 0.75% in presbyopia, a post-hoc MIRA-2 optical-impact analysis of RYZUMVI, and an encore LYNX-2 mesopic-vision study.
Opus noted a Viatris-funded educational symposium on April 11; Viatris holds exclusive U.S. commercialization rights under a global license for phentolamine 0.75%.
Opus Genetics (Nasdaq: IRD) secured a strategic financing facility with Oberland Capital that provides up to $155 million of primarily non-dilutive capital, including an $35 million initial tranche and a concurrent $5 million equity investment at $4.48 per share.
With ~$100 million pro forma cash, Opus says this extends runway into 2029 to complete pivotal OPGx-LCA5 and OPGx-BEST1 studies and to advance three earlier-stage programs toward clinical testing in 2026–2027.
Opus Genetics (Nasdaq: IRD) was named to Fast Company’s World’s Most Innovative Companies 2026 list in the Biotech category on March 24, 2026. The recognition highlights Opus Genetics’ patient-centered gene therapy work, including programs OPGx-BEST1 and OPGx-LCA5 targeting inherited retinal diseases.
The company emphasized its novel patient engagement approach and progress across a differentiated pipeline aimed at restoring vision and preventing blindness in ultra-rare IRDs.
Opus Genetics (Nasdaq: IRD) reported 2025 results and a corporate update on March 10, 2026. Key highlights include $45.1M cash at year-end and subsequent ~$25.0M private placement, implying $70.1M aggregate resources expected to fund operations into H1 2028.
Clinical progress: positive early safety and efficacy signals from OPGx-BEST1 (12-letter BCVA gain; 23% CST reduction), Phentolamine sNDA accepted with PDUFA date Oct 17, 2026, LYNX-3 topline H1 2026, OPGx-LCA5 pivotal dosing expected H2 2026, and funding secured for OPGx-MERTK development.
Opus Genetics (Nasdaq: IRD) announced management will present at three investor conferences in March 2026: Leerink Global Healthcare (Mar 10, 3:00 p.m. ET, Miami), Citizens Life Sciences (Mar 11, 2:50 p.m. ET, Miami), and RBC Capital Markets Global Ophthalmology (Mar 25, 11:45 a.m. ET, virtual).
Links to webcasts are available on the company's Investors > Events webpage.
Opus Genetics (Nasdaq: IRD) reported 3-month sentinel participant data for its Phase 1/2 OPGx-BEST1 gene therapy for BEST1-related retinal disease.
The treated 63-year-old participant showed no ocular inflammation, no treatment-related adverse events, and no dose-limiting toxicities. Efficacy signals included a 12-letter BCVA gain and 23% central subfield thickness (CST) reduction at three months. Full Cohort 1 data expected mid-year 2026.
Opus Genetics (Nasdaq: IRD) announced the FDA has accepted the supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia, with a PDUFA goal date of October 17, 2026.
Phase 3 trials VEGA-2 and VEGA-3 met primary and all key secondary endpoints with no treatment-related serious adverse events. RYZUMVI is already approved in the U.S. for pharmacologic mydriasis, and Opus has a global U.S. commercialization license with Viatris. VEGA-3 data will be presented at ASCRS (April 2026) and ARVO (May 2026).
Opus Genetics (Nasdaq: IRD) agreed to a $25.0 million private placement of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock at $3.39 per share. The preferred stock is expected to automatically convert one-for-one into common stock, subject to shareholder approval to increase authorized shares.
The financing is led by Adage Capital Management with participation from Trails Edge Capital Partners and Marshall Wace, is expected to close on February 18, 2026, and proceeds will fund gene therapy programs, working capital and general corporate purposes. Opus Genetics expects year-end 2025 pro forma cash of $70 million, which it says should fund operations into the first half of 2028.
Opus Genetics (Nasdaq: IRD) announced leadership participation in multiple ophthalmology and industry conferences in February 2026, presenting clinical and manufacturing updates.
Events include CCOI (Feb 3-4, Hong Kong), APAO (Feb 5-8, Hong Kong), Advanced Therapies Week (Feb 11, San Diego) and Macula Society (Feb 27, San Diego).